Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
- Palich, Romain
- Veyri, M.
- Marot, S.
- Vozy, A.
- Gligorov, J.
- Maingon, P.
- Marcelin, A.-G.
- Spano, J.-P.
DOIAbstract
International audienceActive cancer and ongoing antineoplastic treatments are major factors for severe COVID-19 and death, reasons why the SARS-CoV-2 vaccination remains a priority in cancer patients (CPs). However, immunocompromised patients were excluded from major studies on mRNA vaccines, and could have a decreased response to vaccination, as recently demonstrated in solid organ transplant recipients. Herein, we aimed to assess the proportion of antibody response 4 weeks after the first injection of the BNT162b2 (Pfizer-BioNTech) vaccine in CPs and health care workers (HCWs) as the control population
Add to ORKG